|
1
|
Jensen MC, Popplewell L, Cooper LJ,
DiGiusto D, Kalos M, Ostberg JR and Forman SJ: Antitransgene
rejection responses contribute to attenuated persistence of
adoptively transferred CD20/CD19-specific chimeric antigen receptor
redirected T cells in humans. Biol Blood Marrow Transplant.
16:1245–1256. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Savoldo B, Ramos CA, Liu E, Mims MP,
Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, et al:
CD28 costimulation improves expansion and persistence of chimeric
antigen receptor-modified T cells in lymphoma patients. J Clin
Invest. 121:1822–1826. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grupp S, Hu ZH, Zhang Y, Keating A,
Pulsipher MA, Philips C, Margossian SP, Rosenthal J, Salzberg D,
Schiff DK, et al: Tisagenlecleucel Chimeric antigen receptor (CAR)
T-cell therapy for relapsed/refractory children and young adults
with acute lymphoblastic leukemia (ALL): Real world experience from
the center for international blood and marrow transplant research
(CIBMTR) and cellular therapy (CT) registry. Blood. 134:2619. 2019.
View Article : Google Scholar
|
|
4
|
Jaglowski S, Hu ZH, Zhang Y, Kamdar M,
Ghosh M, Lulla P, Sasine J, Perales MA, Hematti P, Nikiforow S, et
al: Tisagenlecleucel Chimeric antigen receptor (CAR) T-cell therapy
for adults with diffuse large B-Cell lymphoma (DLBCL): Real world
experience from the center for international blood & marrow
transplant research (CIBMTR) cellular therapy (CT) registry. Blood.
134:766. 2019. View Article : Google Scholar
|
|
5
|
Nastoupil LJ, Jain MD, Feng L, Spiegel JY,
Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, et al:
Standard-of-care axicabtagene ciloleucel for relapsed or refractory
large B-cell lymphoma: Results from the US lymphoma CAR T
Consortium. J Clin Oncol. 38:3119–3128. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pasquini MC, Locke FL, Herrera AF, Siddiqi
T, Ghobadi A, Komanduri KV, Hu ZH, Dong H, Hematti P, Nikiforow S,
et al: Post-marketing use outcomes of an Anti-CD19 Chimeric antigen
receptor (CAR) T cell therapy, Axicabtagene Ciloleucel (Axi-Cel),
for the treatment of large B cell lymphoma (LBCL) in the United
States (US). Blood. 134:764. 2019. View Article : Google Scholar
|
|
7
|
European Medicines Agency:
Yescarta-Axicabtagene Ciloleucel. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta.
|
|
8
|
European Medicines Agency:
Kymriah-tisagenlecleucel. https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah.
|
|
9
|
European Medicines Agency:
Tecartus-Autologous peripheral blood T cells CD4 and CD8 selected
and CD3 and CD28 activated transduced with retroviral vector
expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and
cultured. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tecartus.
|
|
10
|
Maude SL, Frey N, Shaw PA, Aplenc R,
Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et
al: Chimeric antigen receptor T cells for sustained remissions in
leukemia. N Engl J Med. 371:1507–1517. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Neelapu SS, Locke FL, Bartlett NL, Lekakis
LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T,
Lin Y, et al: Axicabtagene Ciloleucel CAR T-cell therapy in
refractory large B-cell lymphoma. N Engl J Med. 377:2531–2544.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Turtle CJ, Hay KA, Hanafi LA, Li D,
Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S, et al:
Durable molecular remissions in chronic lymphocytic leukemia
treated with CD19-specific chimeric antigen receptor-modified T
cells after failure of Ibrutinib. J Clin Oncol. 35:3010–3020. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Maude SL, Laetsch TW, Buechner J, Rives S,
Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers
GD, et al: Tisagenlecleucel in Children and Young Adults with
B-cell lymphoblastic leukemia. N Engl J Med. 378:439–448. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schuster SJ, Bishop MR, Tam CS, Waller EK,
Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin
JR, et al: Tisagenlecleucel in adult relapsed or refractory diffuse
large B-cell lymphoma. N Engl J Med 3. 80:45–56. 2019. View Article : Google Scholar
|
|
15
|
Locke FL, Ghobadi A, Jacobson CA, Miklos
DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT,
Timmerman JM, et al: Long-term safety and activity of axicabtagene
ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A
single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20:31–42.
2019. View Article : Google Scholar :
|
|
16
|
Ayuk FA, Berger C, Badbaran A, Zabelina T,
Sonntag T, Riecken K, Geff ken M, Wichmann D, Frenzel C, Thayssen
G, et al: Axicabtagene ciloleucel in vivo expansion and treatment
outcome in aggressive B-cell lymphoma in a real-world setting.
Blood Adv. 5:2523–2527. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fehse B, Badbaran A, Berger C, Sonntag T,
Riecken K, Geffken M, Kröger N and Ayuk FA: Digital PCR assays for
precise quantification of CD19-CAR-T cells after treatment with
axicabtagene ciloleucel. Mol Ther Methods Clin Dev. 16:172–178.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Badbaran A, Berger C, Riecken K, Kruchen
A, Geffken M, Müller I, Kröger N, Ayuk FA and Fehse B: Accurate
In-vivo quantification of CD19 CAR-T cells after treatment with
Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel)
Using Digital PCR. Cancers (Basel). 12:19702020. View Article : Google Scholar
|
|
19
|
Kunz A, Gern U, Schmitt A, Neuber B, Wang
L, Hückelhoven-Krauss A, Michels B, Hofmann S, Müller-Tidow C,
Dreger P, et al: Optimized assessment of qPCR-based vector copy
numbers as a safety parameter for GMP-grade CAR T cells and
monitoring of frequency in patients. Mol Ther Methods Clin Dev.
17:448–454. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schubert ML, Kunz A, Schmitt A, Neuber B,
Wang L, Hückelhoven-Krauss A, Langner S, Michels B, Wick A, Daniel
V, et al: Assessment of CAR T cell frequencies in axicabtagene
ciloleucel and tisagenlecleucel patients using duplex quantitative
PCR. Cancers. 12:28202020. View Article : Google Scholar :
|
|
21
|
Cheson BD, Ansell S, Schwartz L, Gordon
LI, Advani R, Jacene HA, Hoos A, Barrington SF and Armand P:
Refinement of the Lugano classification lymphoma response criteria
in the era of immunomodulatory therapy. Blood. 128:2489–2496. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Appelbaum FR, Rosenblum D, Arceci RJ,
Carroll WL, Breitfeld PP, Forman SJ, Larson RA, Lee SJ, Murphy SB,
O'Brien S, et al: End points to establish the efficacy of new
agents in the treatment of acute leukemia. Blood. 109:1810–1816.
2007. View Article : Google Scholar
|
|
23
|
Lee DW, Santomasso BD, Locke FL, Ghobadi
A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, et
al: ASTCT consensus grading for cytokine release syndrome and
neurologic toxicity associated with immune effector cells. Biol
Blood Marrow Transplant. 25:625–638. 2019. View Article : Google Scholar
|
|
24
|
Sequence of the FMC63-28Z receptor protein
gene. Available from: https://www.ncbi.nlm.nih.gov/nuccore/HM852952.1.
|
|
25
|
Turtle CJ, Hanafi LA, Berger C, Hudecek M,
Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, et
al: Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of
CD8+ and CD4+ CD19-specific chimeric antigen
receptor-modified T cells. Sci Transl Med. 8:355ra1162016.
View Article : Google Scholar
|
|
26
|
Awasthi R, Pacaud L, Waldron E, Tam CS,
Jäger U, Borchmann P, Jaglowski S, Foley SR, van Besien K,
Wagner-Johnston ND, et al: Tisagenlecleucel cellular kinetics,
dose, and immunogenicity in relation to clinical factors in
relapsed/refractory DLBCL. Blood Adv. 4:560–572. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Santomasso BD, Park JH, Salloum D, Riviere
I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, et al:
Clinical and biological correlates of neurotoxicity associated with
CAR T-cell therapy in patients with B-cell acute lymphoblastic
leukemia. Cancer Discov. 8:958–971. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ayuk F, Fehse B, Janson D, Berger C,
Riecken K and Kröger N: Excellent proliferation and persistence of
allogeneic donor-derived 41-BB based CAR-T cells despite
immunosuppression with cyclosporine A. Haematologica. 105:322–324.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu Y and Huang J: The chimeric antigen
receptor detection toolkit. Front Immunol. 11:17702020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang W, Nilles TL, Johnson JR and
Margolick JB: The effect of cellular isolation and cryopreservation
on the expression of markers identifying subsets of regulatory T
cells. J Immunol Methods. 431:31–37. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Demaret J, Varlet P, Trauet J, Beauvais D,
Grossemy A, Hégo F, Yakoub-Agha I and Labalette M: Monitoring CAR
T-cells using flow cytometry. Cytometry B Clin Cytom. 100:218–224.
2021. View Article : Google Scholar
|
|
32
|
Schanda N, Sauer T, Kunz A,
Hückelhoven-Krauss A, Neuber B, Wang L, Hinkelbein M, Sedloev D, He
B, Schubert ML, et al: Sensitivity and specificity of CD19.CAR-T
cell detection by flow cytometry and PCR. Cells. 10:32082021.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kawalekar OU, O'Connor RS, Fraietta JA,
Guo L, McGettigan SE, Posey AD Jr, Patel PR, Guedan S, Scholler J,
Keith B, et al: Distinct signaling of coreceptors regulates
specific metabolism pathways and impacts memory development in CAR
T Cells. Immunity. 44:380–390. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kowolik CM, Topp MS, Gonzalez S, Pfeiffer
T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC and
Cooper LJ: CD28 costimulation provided through a CD19-specific
chimeric antigen receptor enhances in vivo persistence and
antitumor efficacy of adoptively transferred T cells. Cancer Res.
66:10995–1004. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Loskog A, Giandomenico V, Rossig C, Pule
M, Dotti G and Brenner MK: Addition of the CD28 signaling domain to
chimeric T-cell receptors enhances chimeric T-cell resistance to T
regulatory cells. Leukemia. 20:1819–1828. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Long AH, Haso WM, Shern JF, Wanhainen KM,
Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara
VR, et al: 4-1BB costimulation ameliorates T cell exhaustion
induced by tonic signaling of chimeric antigen receptors. Nat Med.
21:581–590. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhao Z, Condomines M, van der Stegen SJC,
Perna F, Kloss CC, Gunset G, Plotkin J and Sadelain M: Structural
design of engineered costimulation determines tumor rejection
kinetics and persistence of CAR T cells. Cancer Cell. 28:415–428.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Milone MC, Fish JD, Carpenito C, Carroll
RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B,
Danet-Desnoyers G, et al: Chimeric receptors containing CD137
signal transduction domains mediate enhanced survival of T cells
and increased antileukemic efficacy in vivo. Mol Ther.
17:1453–1464. 2009. View Article : Google Scholar : PubMed/NCBI
|
